Suggested remit - To appraise the clinical and cost effectiveness of treosulfan with fludarabine within its marketing authorisation as a conditioning treatment for malignant diseases prior to allogeneic haematopoietic stem cell transplantation
 
Status In progress
Process STA 2018
ID number 1508

Provisional Schedule

Committee meeting: 2 28 January 2020
Expected publication 05 February 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Medac
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Anthony Nolan
  Lymphoma Action
  Leukaemia Care
Professional groups Royal College Of Radiologist
  Royal College of Physicians

Commentators

General commentators All Wales Therapeutics and Toxicology Centre
  Department of Health and Social Services and Public Safety, Northern Ireland (DHSSPSNI)
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
12 November 2019 Committee meeting: 1
14 March 2019 Invitation to participate
13 March 2019 In progress, In progress
09 November 2018 - 07 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance